^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Glioma

Related cancers:
23h
Cerebrospinal fluid cfDNA-based molecular assessment of resection extent and prognosis in glioma. (PubMed, Commun Med (Lond))
These findings suggest that CSF cfDNA effectively represents the genetic profile of gliomas and serves as a sensitive measure for surgical resection efficacy and patient prognosis, highlighting its potential as a non-invasive biomarker for enhancing post-operative management in glioma patients.
Journal • Tumor mutational burden
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • TERT (Telomerase Reverse Transcriptase)
|
TP53 mutation • PTEN mutation
23h
18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitors. (PubMed, Clin Cancer Res)
These results highlight the potential of ¹⁸F-DOPA-PET and advanced MRI sequences as valuable complements to standard RANO 2.0 MRI evaluations for assessing treatment response in glioma patients undergoing IDHi therapy.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
Tibsovo (ivosidenib) • Voranigo (vorasidenib)
1d
New trial
1d
Multi-Omics Evidence Based on Spatial Transcriptomics Data Reveals the Therapeutic Value of Copper Death Genes in Glioblastoma. (PubMed, Int J Genomics)
Furthermore, miR-93-5p was validated as a critical gene, with its disruption leading to significant reductions in GBM cell proliferation, migration, and invasion. The novel CRM signature enhances the prognostic landscape for patients with LGG, offering a new framework for evaluating immunotherapeutic efficacy.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • MIR93 (MicroRNA 93)
1d
Hypoxia-Induced Osteopontin-Positive Glioma-Associated Macrophages Facilitate Glioma Mesenchymal Transition via NF-κB Pathway Activation. (PubMed, Cancer Commun (Lond))
The inhibition of OPN increased GBM sensitivity to temozolomide (TMZ) in orthotopic models. This study revealed the potential mechanism by which hypoxia-induced OPN+ GAMs promote the mesenchymal transition in GBM cells and demonstrated the therapeutic potential of targeting OPN to enhance TMZ treatment effectiveness.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • SPP1 (Secreted Phosphoprotein 1) • WDR5 (WD Repeat Domain 5)
|
PD-L1 expression
|
temozolomide
1d
Hematological Malignancies With Multiple Primary Cancers: A Rare Case Presentation. (PubMed, Case Rep Hematol)
An increased prevalence of second primary malignancy is anticipated due to the rising cancer burden and the careful screening of index initial malignancy throughout therapy. Determining the best course of action requires careful staging of the cancer and discussion by a multidisciplinary team.
Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
1d
Exploring CSF microRNA signatures as diagnostic biomarkers in adult-type diffuse gliomas. (PubMed, Noncoding RNA Res)
Ingenuity Pathway Analysis (IPA) revealed that miR-16-5p and other miRNAs with seed AGCAGCA formed the largest interaction network in GBM, while disease enrichment analysis using Database for Annotation, Visualization, and Integrated Discovery (DAVID) confirmed that the 1000 predicted mRNA targets of DE-miRNAs in GBM were disease relevant. Collectively, these findings identify a robust panel of CSF-derived miRNAs capable of distinguishing IDH-mutant gliomas, GBM, and non-tumor states, supporting the potential of EV-miRNAs as minimally invasive biomarkers for the molecular characterization of diffuse gliomas.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MIR21 (MicroRNA 21) • MIR142 (MicroRNA 142) • MIR16 (MicroRNA 16) • MIR19B1 (MicroRNA 19b-1) • MIR27B (MicroRNA 27b) • MIR99A (MicroRNA 99a) • MIR150 (MicroRNA 150) • MIR195 (MicroRNA 195) • MIR26A1 (MicroRNA 26a-1) • MIR30A (MicroRNA 30a) • MIR30E (MicroRNA 30e)
|
IDH wild-type
1d
Breaking down glioma primary cilia disassembly. (PubMed, Neurooncol Adv)
Thus, clarifying these alternate mechanisms may be important as the roles of cilia in tumor formation and propagation, angiogenesis, and treatment resistance are increasingly reported. A deeper understanding of the role of cilia in these hallmarks of glioma may hold clues to the high recurrence rate of GBM.
Review • Journal
|
AURKA (Aurora kinase A)
1d
The role of ASIC2 in glioma progression: implications for prognosis and therapeutic targeting. (PubMed, PeerJ)
Functional experiments demonstrate that both knockdown and overexpression of ASIC2 critically regulate glioma cell proliferation, invasion, and metastatic potential through mechanisms mediated by matrix metalloproteinase 2 (MMP2), calcineurin, and nuclear factor of activated T cells 1 (NFAT1) signaling pathways. These findings delineate a pivotal role for ASIC2 in governing glioma malignant behavior and establish its relevance as a potential molecular target for therapeutic intervention.
Journal
|
MMP2 (Matrix metallopeptidase 2) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
1d
Expression Characteristics and Prognostic Study of PPP1R13L in Brain Metastases of Lung Adenocarcinoma (PubMed, Zhongguo Fei Ai Za Zhi)
This study revealed the interaction between epithelial cells and fibroblasts in the microenvironment of lung adenocarcinoma brain metastasis and implicate PPP1R13L as a potential prognostic indicator and actionable target, offering rationale for precision therapy against lung adenocarcinoma brain metastases.
Journal
|
COL1A1 (Collagen Type I Alpha 1 Chain)
2d
Identification of Glioma Phenotypic Subtypes From Multimodal MRI Data Using Hierarchical Multi-Kernel Learning. (PubMed, Cancer Med)
Our study provides a non-invasive method to identify glioma phenotypic subtypes, reveal distinct signaling pathways, and define therapeutically homogeneous patient subgroups that could guide targeted therapy.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
2d
Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT) (clinicaltrials.gov)
P=N/A, N=94, Recruiting, Tata Memorial Centre | Phase classification: P3 --> P=N/A
Phase classification